Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nektar settles patent dispute with University
The University of Alabama in Huntsville (UAH) brought litigation against Nektar and Dr Milton Harris, a former employee of the university, claiming that the company’s portfolio of products
The University of Alabama in Huntsville (UAH) brought litigation against Nektar and Dr Milton Harris, a former employee of the university, claiming that the company’s portfolio of products
The data from the recently completed trial showed that Sanctura XR met its primary endpoints, reduction in frequency of urination and reduction in number of urge incontinence episodes.
The grant, awarded through the small business innovation research (SBIR) program, will support phase II safety and efficacy studies of PMI-150 in a multicenter, randomized, double blind, and
The companies said that the restructuring is mutually beneficial based upon a review of each company’s long-term business strategies and objectives. The restructured agreement will allow Wyeth to
The study will be conducted at up to 25 sites in the US and will enroll approximately 84 patients, with the intention that approximately half of the patients
The completion of current good manufacturing practices (cGMP) manufacture of RiVax forms one of the crucial milestones in the development of the vaccine, which is being conducted under
This study is part of a major drug development program to evaluate the prevention and treatment of dyslipidemia, atherosclerosis, and coronary heart disease. Pacific will provide the sponsor
BioMap profiling can provide in-depth characterization of drug function, including defining mechanism of action and secondary activities, and can provide insights into potential clinical applications. BioMap systems are
The study will be conducted in the US and Canada and involves about 50 clinical centers. More than 2,000 patients will be included in the study and 1,270
Investigators will assess the efficacy, as well as the safety and tolerability, of ALS-08 in separate combinations with celecoxib (marketed as Celebrex by Pfizer) and minocycline in patients